Alexandra MacLean, Avenue Therapeutics CEO
April 18, 2023 11:05 AM EDT
FDA+

Av­enue touts progress with FDA on em­bat­tled pain can­di­date af­ter two CRLs, failed ad­comm

Paul Schloesser

Associate Editor

Av­enue Ther­a­peu­tics says it is most­ly in agree­ment with FDA on tri­al pro­to­cols for a po­ten­tial Phase III safe­ty study, which could lead to the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Halozyme with­draws Evotec ac­qui­si­tion pro­pos­al af­ter biotech is 'un­will­ing to en­gage'

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times